Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, placebo-controlled, phase 1/2 clinical study in Japan

Mitsuyoshi Tanishima, Kayo Ibaraki, Keishi Kido, Shun Nakayama, Kohei Ata, Hideki Nakamura, Yasuhiko Shinmura, Masafumi Endo, Kengo Sonoda, Kohji Ueda, Yoshiaki Oda
doi: https://doi.org/10.1101/2022.06.28.22276794

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Back to top
Posted June 29, 2022.
Download PDF
Data/Code
Email
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, placebo-controlled, phase 1/2 clinical study in Japan
Mitsuyoshi Tanishima, Kayo Ibaraki, Keishi Kido, Shun Nakayama, Kohei Ata, Hideki Nakamura, Yasuhiko Shinmura, Masafumi Endo, Kengo Sonoda, Kohji Ueda, Yoshiaki Oda
medRxiv 2022.06.28.22276794; doi: https://doi.org/10.1101/2022.06.28.22276794
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area